{"url_path":"/sec/alzn/10-k/2026/item-9b","section_key":"item-9b","section_title":"Item 9B ****OTHER INFORMATION**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1677077/0001214659-26-008832-index.html","accession_number":"0001214659-26-008832","cik":"0001677077","ticker":"ALZN","issuer_name":"Alzamend Neuro, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1677077/0001214659-26-008832-index.html","primary_entity_key":"0001677077","primary_entity_name":"Alzamend Neuro, Inc."},"word_count":46,"has_tables":true,"body_markdown":"**ITEM 9B.****OTHER INFORMATION**\n\n \n\n**Trading Plans**\n\n \n\nDuring the three months ended\nApril 30, 2026, no director or Section 16 officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement”\nor “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K."}